A Double-Blind, Randomized, Placebo-controlled, 3-Way Cross Over Study to Evaluate the Efficacy and Safety of 14 Days TPI ASM8 in Subjects With Asthma.

Trial Profile

A Double-Blind, Randomized, Placebo-controlled, 3-Way Cross Over Study to Evaluate the Efficacy and Safety of 14 Days TPI ASM8 in Subjects With Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2012

At a glance

  • Drugs ASM 8 (Primary)
  • Indications Allergic asthma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 02 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Results of this trial are anticipated in the second quarter of 2012, according to a Pharmaxis media release.
    • 29 Sep 2011 Pharmaxis confirms the completion of patient enrolment in a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top